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Introduction
Pancreatic cancer remains one of the most aggressive
malignancies which has a mortality nearly parallel to
incidence. In the United States, for example, statistics from
the National Cancer Institute’s Surveillance, Epidemiology,
and End Results (SEER) Program estimates 55,440 new
cases of pancreatic cancer in the U.S. in 2018, with 44,330
estimated deaths (1). Based on data collected from 2008–
2014, only 8.5% of patients survive 5 years or longer (1). It
is widely held that a combination of surgical resection and
systemic chemotherapy provides the optimal treatment for
pancreatic cancer. Unfortunately, only about 15–20% of
patients present with resectable disease.
Surgical resectability previously had taken presence
of metastatic disease or vascular involvement into
consideration. Anatomic vascular involvement was
classified into groupings based on vascular involvement,
from abutment <180° to encasement. A 2017 international
consensus also reported biologic factors that should be
considered in the definition of borderline-resectable
pancreatic cancer (2). Serum CA 19-9 of >500 IU/mL and/
or positive regional lymph node metastases based on biopsy
or PET-CT scan was added to the anatomic definition, as
was a conditional definition of poor performance status,
with PS of 2 or greater (2). National cancer care guidelines,
including the U.S. NCCN guidelines and European Society
of Medical Oncology, both suggest inclusion in clinical
trials if possible, for patients with borderline resectable or
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locally advanced disease. If not treated within the context
of a clinical trial, both suggest a trial of chemotherapy and
potential radiation to improve margin-negative resection
(3,4); however, this is not supported by high-level trials.
Because it is unknown what the optimal treatment sequence
and strategy should be, ongoing investigation is being
performed looking at predictive models.
Discussion
Choi et al. have recently created a nomogram for prediction
of overall survival in patients with locally advanced pancreatic
cancer treated with chemoradiotherapy (5). In this study, the
authors evaluated 426 patients with borderline resectable
or locally advanced pancreatic cancer who underwent
chemoradiotherapy between 1/2004 and 12/2015 and had
pre-treatment PET/CT scans and CA19-9 levels. Univariate
analysis demonstrated surgical resection, pre-treatment
SUVmax <3.5, SUV decline rate ≥60%, pre-treatment CA
19-9 ≤400 U/mL, post-treatment CA 19-9 ≤100 U/mL,
and a CA 19-9 decline rate >40% were independently
significant for predicting improved progression free
survival. In consideration of overall survival, a total radiation
dose ≥61 Gy and IMRT was also significant in addition
to the previously mentioned factors. In multivariate
analysis, however, surgical resection, pre-treatment
SUVmax <3.5 and pre-treatment CA 19-9 ≤400 U/mL
are the only factors predictive of both overall and
progression-free survival. Radiation dose ≥61 Gy was also
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predictive of improved overall survival (5). Based on these
data, a nomogram was constructed including the variables
high RT dose ≥61 Gy, surgical resection, pre-treatment
SUV <3.5, and pre-treatment CA 19-9 ≤400 U/mL. Three
groups were stratified based on accumulated points: lowrisk, intermediate-risk, and high-risk, with significantly
different overall survival based on grouping. The authors
propose that this nomogram would be helpful for patient
consultation and treatment decision-making in clinical
practice (5).
The authors should be commended on compiling a
nomogram from a robust dataset; however, the utilization
of the nomogram may not be widely applicable, and several
factors must be considered. Firstly, there is a marked
difference in patients with borderline resectable vs. locally
advanced pancreatic cancer. Resection rates are higher in
borderline resectable pancreatic cancer patients vs. locally
advanced patients following neoadjuvant chemoradiation,
typically with a gemcitabine or 5-fluorouracil based
regimen (6). It is unclear if combining the two groups of
borderline resectable and locally advanced pancreatic cancer
patients impacts the nomogram predictive model than if
each group was considered in isolation. Secondly, another
metric that is significant in the nomogram is high-dose
radiation, of 61 Gy. Most recommendations for neoadjuvant
chemoradiation, including recommendations of the NCCN,
are for doses of 45–54 Gy. Doses higher than 54 Gy could be
considered in the context of a clinical trial (4). Conventional
doses of radiation do not seem to significantly affect survival
based on the authors’ dataset, and it is unclear why patients
received such high doses of radiation.
Another factor to consider is the time frame of the
nomograph dataset, which spans from 1/2004–12/2015;
this may explain why 50% received gemcitabine-based
concurrent chemotherapy. The other 50% received an
unspecified regimen. Since 2011, two regimens have been
approved as first-line chemotherapy for pancreatic cancer,
applied to both borderline resectable and locally advanced
patients: gemcitabine in combination with nab-paclitaxel
and FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan
and oxaliplatin) (7). These regimens have had more success
in treating patients compared with gemcitabine-alone,
so it is unknown whether these regimens have a greater
impact and thus survival in the later data set years. Parsing
out chemotherapy regimens may help understand the true
impact of specific chemotherapy regimens, rather than
broadly considering chemotherapy as a variable.
Surgical resection remains one of the mainstays of
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therapy and improved survival. With respect to borderline
resectable and locally advanced patients, resection
feasibility is often dependent upon not only the response to
neoadjuvant chemoradiation but also the surgical treatment
team and their experience with vascular reconstruction.
Although all of the study patients were treated at a single
institution, it is unknown how many patients required
concomitant vascular reconstruction and how many
achieved a R0 resection.
One of the unique aspects of this study is the inclusion
of biologic factors, including pre-treatment CA19-9, pretreatment SUV value and SUV change with treatment,
although ultimately the SUV change was not found to
be predictive of overall survival. Many studies have also
suggested that an elevated CA19-9 is suggestive of worse
prognosis and potentially micrometastatic disease (2).
Interestingly, the SUV change was not found to predict
survival; perhaps other criteria, such as RECIST
radiographic criteria, would also be useful. Thus, while the
inclusion of biologic factors is important, it is still unclear
how they should be utilized as the patient progresses
through neoadjuvant treatment.
Conclusions
In conclusion, this current nomogram incorporates many
factors already determined to be predictive of aggressive
disease, including elevated CA19-9 and PET-avid disease.
The nomogram incorporates high-dose radiation, which
is uncommonly utilized; therefore, it is unclear if this
nomogram should be utilized, since this would be an
uncommon factor to consider. It is commendable that the
authors have produced a model that may assist clinical
decision-making; however, it is unclear if this truly would
impact patient care. For instance, would a patient with a
high-risk nomogram but resectable disease anatomically
not be recommended to undergo resection? Clearly, further
investigation is required, evaluating various situations to
determine best practice.
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